Visit Booth #5 August 18–20 at the Capital Hilton
Carlsbad, CA — DCN Dx, a specialist in lateral flow diagnostics development, manufacturing, and IVD regulatory consulting and clinical research, will exhibit at the 2025 Next Generation Dx Summit, taking place August 18–20 at the Capital Hilton in Washington, DC. Attendees can visit DCN Dx at Booth #5 to explore how the company’s integrated IVD CRO and CDMO services support diagnostic innovation from concept through commercialization.
DCN Dx’s team will be available to discuss custom support across clinical trial design and execution, regulatory strategy and submission, assay development, and device manufacturing. The company’s miniDxR™, a compact point-of-care reader platform, will also be available for hands-on demonstrations.
“Our integrated service model is uniquely suited for diagnostic developers navigating both technical challenges and regulatory complexity,” said Charlie Mamrak, CEO of DCN Dx. “We look forward to engaging with the NextGen Dx audience and exploring how our CRO and CDMO offerings can help bring innovative products to market.”
NextGen Dx 2025 brings together global leaders to discuss the latest advances in point-of-care testing, infectious disease diagnostics, liquid biopsy, multi-cancer early detection, and regulatory and reimbursement trends. The show provides a platform for collaboration across the full diagnostic ecosystem, with a focus on accelerating technologies that improve patient care.
To request a meeting with the DCN Dx team during the event, visit https://shorturl.at/yHW9w.
About DCN Dx
DCN Dx, based in Carlsbad, California, specializes in lateral flow diagnostics development and manufacturing, and IVD regulatory consulting and clinical research. DCN Dx’s multidisciplinary CDMO specializes in creating tailored assay systems, consumables, and instruments for point-of-use applications, with a particular expertise in lateral flow assays. Their clinical research services group specializes in the planning, execution, and oversight of IVD clinical trials, inclusive of clinical operations, data management, and biostatistics, and regulatory services.
DCN Dx’s personalized approach to IVD product development and clinical trials has supported hundreds of programs and clients. They can oversee every stage from concept to assay development and platform integration, through clinical trials to manufacturing or only handle the aspects you request. In addition to lateral flow assays, DCN Dx’s clinical research expertise extends to any in vitro diagnostic, all with a focus on innovation, usability, and performance.
With a commitment to quality, customer satisfaction, and industry-leading expertise, DCN Dx is setting the benchmark for excellence in IVD services. To learn more about how we can support your diagnostic needs, visit dcndx.com.
For more information contact:
Mitzi Rettinger
Chief Revenue Officer
DCN Dx
mrettinger@dcndx.com
(760) 804-3886
